Bildkälla: Stockfoto

Sprint Bioscience Q2: Brief comment on the report - Redeye

Redeye provides a brief comment on Sprint Bioscience’s Q2 report. We will soon return with a more extensive take on the case in light of the VADA licensing agreement and where we will likely increase our base case.

Redeye provides a brief comment on Sprint Bioscience’s Q2 report. We will soon return with a more extensive take on the case in light of the VADA licensing agreement and where we will likely increase our base case.
Börsvärldens nyhetsbrev
ANNONSER